Physician profile
Bibi Das
NPI 1528012374
$1,370,438.03
in general payments reported to CMS, 2019-2025
18 companies · $392K in 2025
The $392K reported for 2025 was more than what 99% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $161K · 2020: $87K · 2021: $56K · 2022: $119K · 2023: $289K · 2024: $266K · 2025: $392K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $393K · Consulting Fee: $222K · Travel and Lodging: $154K · Honoraria: $151K · Food and Beverage: $28K · Education: $173.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $393,157.00 |
| Consulting Fee | $221,667.00 |
| Travel and Lodging | $154,232.49 |
| Honoraria | $150,662.50 |
| Food and Beverage | $27,730.77 |
| Education | $172.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $426,872.39 | 2022-2025 | Auvelity, Sunosi |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $272,845.39 | 2020-2025 | Caplyta |
| Abbvie INC. | $170,286.37 | 2021-2025 | Vraylar |
| Allergan, INC. | $126,612.61 | 2019-2020 | |
| Neurocrine Biosciences, INC. | $92,007.55 | 2022-2025 | Ingrezza |
| Sunovion Pharmaceuticals INC. | $89,648.96 | 2019-2021 | |
| Otsuka America Pharmaceutical, INC. | $79,562.82 | 2019-2025 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $54,256.14 | 2019-2025 | Uzedy, Austedo, Austedo Xr |
| Vanda Pharmaceuticals INC. | $32,523.03 | 2019-2025 | Fanapt |
| E.R. Squibb & Sons, L.L.C. | $23,288.93 | 2024-2025 | Cobenfy |
| Takeda Pharmaceuticals U.S.A., INC. | $1,408.12 | 2019-2025 | Trintellix |
| Lundbeck LLC | $709.68 | 2019-2025 | Rexulti |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $141.71 | 2019-2025 | Rexulti |
| Corium, LLC | $76.75 | 2023 | Adlarity |
| Alkermes, INC. | $71.70 | 2021-2022 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $54.56 | 2024 | |
| Shire North American Group INC | $44.63 | 2019 | |
| Indivior INC. | $26.69 | 2023 | Perseris |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bibi Das listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.